Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. (ver web)
(coautores junto a González JL, Prior C, Castellano D, Mellado B, Gallardo E, Perez JL,, Villanueva X, Albanell J, Calvo A). Ann Oncol. 2011 Mar 21.